Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Edition
European
US
Rheumatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
The first and only approved dual inhibitor of IL-17A and IL-17F1-6
February 2026
BIMZELX® Demonstrated Deep and Sustained Efficacy to 3 Years Across Multiple Disease Domains of PsA and the Full axSpA Spectrum…
Read more
9
Mins
15 Jul 2021
Mind the Gap: Balancing Remission and Risk of Relapse in ANCA-Associated Vasculitis
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an umbrella term for a group of rare, multisystem autoimmune…
2
Mins
15 Jul 2021
Association Between Environmental Air Pollution and Rheumatoid Arthritis Flares
Environmental air pollution has been linked to the pathogenesis of rheumatoid arthritis (RA).1 Nevertheless, there is no evidence linking higher concentrations of air pollutants with the risk of RA reactivations.
9
Mins
15 Jul 2021
Striking the Right Balance in Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis
AAV are a type of small-vessel necrotising vasculitis that manifest as systemic diseases, with pulmonary; ear, nose, and throat; and renal involvement. The key pathological feature of AAV is the presence of ANCA, which can target two neutrophil antigens, myeloperoxidase (MPO) and proteinase 3 (PR3).
2
Mins
15 Jul 2021
Efficacy and Safety of TNF-α Antagonists and Tocilizumab in Takayasu Arteritis: Multi-centre, Retrospective Study of 209 Patients
Takayasu arteritis (TA) is a chronic inflammatory large-vessel vasculitis, predominantly affecting the aorta and its main branches.
5
Mins
15 Jul 2021
EULAR Interview: Joan Bathon
Joan Bathon | Member of the EULAR Scientific Programme Committee; Director of the Division of Rheumatology at New York-Presbyterian Hospital…
6
Mins
15 Jul 2021
Interview: Christopher Edwards
Christopher Edwards | Professor and Consultant Rheumatologist and Honorary Chair of Clinical Rheumatology; Musculoskeletal Research Unit…
2
Mins
15 Jul 2021
RESOLVE-1, a Phase III Trial of Lenabasum for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Lenabasum is an oral, non-immunosuppressive, cannabinoid Type 2 receptor agonist that activates resolution of innate immune responses.1 In animal models of bleomycin-induced skin and lung fibrosis, lenabasum reduced inflammation and fibrosis
5
Mins
15 Jul 2021
EULAR Interview: Ricardo Ferreira
Ricardo Ferreira | Chair of the EULAR Committee of Health Professionals in Rheumatology; Clinical Research Nurse and Study Coordinator…
Loading posts...
« Previous
1
…
48
49
50
51
52
…
83
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View